Literature DB >> 19329854

Factors influencing long-term survival in patients with T3 gallbladder adenocarcinoma.

K Dilip Chakravarty1, Chun-Nan Yeh, Yi-Yin Jan, Miin-Fu Chen.   

Abstract

PURPOSE: This study aimed to identify the factors influencing the surgical outcome in patients with T3 gallbladder adenocarcinoma (GBA).
METHODS: Between 1996 and 2006, 100 GBA patients who underwent surgical treatment in Chang Gung Memorial Hospital, Taiwan, were retrospectively reviewed. Among them, 39 patients with pathological stage T3 GBA were analyzed statistically in terms of demographic data and clinicopathological features.
RESULTS: The 1-, 3- and 5-year survival rates for patients with T3 GBA undergoing surgical treatment were 53.5, 37.0 and 32.9%, respectively. Univariate survival analysis revealed male gender, low serum carcinoembryonic antigen (CEA) level, and curative resection as factors which predicted favorable overall survival for T3 GBA patients. Multivariate survival analysis revealed low preoperative CEA levels and curative resections independently predicted favorable outcomes.
CONCLUSIONS: Negative resection margin and serum CEA levels were found to be the independent prognostic factors in predicting long-term survival in patients with T3 GBA, and the serum CEA level was also found to be an independent prognostic factor in predicting the long-term prognosis of T0-T4 GBA; however, the result is preliminary due to the limited number of patients. Further studies with a large number of patients are necessary to confirm our result.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19329854     DOI: 10.1159/000210131

Source DB:  PubMed          Journal:  Digestion        ISSN: 0012-2823            Impact factor:   3.216


  8 in total

Review 1.  Key factors influencing prognosis in relation to gallbladder cancer.

Authors:  Charles Henry Caldow Pilgrim; Ryan T Groeschl; Kiran K Turaga; T Clark Gamblin
Journal:  Dig Dis Sci       Date:  2013-05-22       Impact factor: 3.199

2.  Surgical outcomes and prognostic factors influencing long-term survival in patients with gallbladder cancer.

Authors:  Sung Ha Lee; Jae Do Yang; Hong Pil Hwang; Hee Chul Yu; Baik Hwan Cho
Journal:  Korean J Hepatobiliary Pancreat Surg       Date:  2012-05-31

3.  Evaluation of a prospective surgical strategy of extended resection to achieve R0 status in gall bladder cancer.

Authors:  Biju Pottakkat; Abhimanyu Kapoor; Anand Prakash; Rajneesh Kumar Singh; Anu Behari; Ashok Kumar; Vinay K Kapoor; Rajan Saxena
Journal:  J Gastrointest Cancer       Date:  2013-03

4.  Tumor Marker Kinetics as Prognosticators in Patients with Unresectable Gallbladder Adenocarcinoma Undergoing Palliative Chemotherapy.

Authors:  Jae Woo Lee; Yong-Tae Kim; Sang Hyub Lee; Jun Hyuk Son; Jin Woo Kang; Ji Kon Ryu; Dong Kee Jang; Woo Hyun Paik; Ban Seok Lee
Journal:  Gut Liver       Date:  2018-01-15       Impact factor: 4.519

5.  Norcantharidin inhibits tumor growth and vasculogenic mimicry of human gallbladder carcinomas by suppression of the PI3-K/MMPs/Ln-5γ2 signaling pathway.

Authors:  Jing-Tao Zhang; Wei Sun; Wen-Zhong Zhang; Chun-Yan Ge; Zhong-Yan Liu; Ze-Ming Zhao; Xing-Sui Lu; Yue-Zu Fan
Journal:  BMC Cancer       Date:  2014-03-15       Impact factor: 4.430

6.  Inhibition of tumor vasculogenic mimicry and prolongation of host survival in highly aggressive gallbladder cancers by norcantharidin via blocking the ephrin type a receptor 2/focal adhesion kinase/paxillin signaling pathway.

Authors:  Hui Wang; Wei Sun; Wen-Zhong Zhang; Chun-Yan Ge; Jing-Tao Zhang; Zhong-Yan Liu; Yue-Zu Fan
Journal:  PLoS One       Date:  2014-05-08       Impact factor: 3.240

7.  Patterns of care and treatment outcomes in older patients with biliary tract cancer.

Authors:  Anne Horgan; Jennifer Knox; Priya Aneja; Lisa Le; Elizabeth McKeever; Mairead McNamara
Journal:  Oncotarget       Date:  2015-12-29

8.  Extended Resections for Advanced Gallbladder Cancer: Results from a Nationwide Cohort Study.

Authors:  H Kuipers; E A J de Savornin Lohman; M van Dooren; A E Braat; F Daams; R van Dam; J I Erdmann; J Hagendoorn; F J H Hoogwater; B Groot Koerkamp; T M van Gulik; P R de Reuver; M T de Boer
Journal:  Ann Surg Oncol       Date:  2020-07-21       Impact factor: 5.344

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.